

nature biotechnology

EDITORIAL

953 Calling all patients

954 This means war

NEWS

955 Big pharma swallows biotech's pride

956 GSK's Harvard cash injection

957 Actemra poised to launch IL-6 inhibitors

958 HAE market heats up

958 mAb quality by design

960 Pharmas partner in venture seeking drug discovery tools

961 EU clone green light

961 Return to sender

962 Western biotechs ponder follow-on possibilities

963 SBIR boost

963 Startups lure oil giants

965 PROFILE: Vera Sharav

967 NEWS FEATURE: Trouble at the office

BIOENTREPRENEUR

BUILDING A BUSINESS

971 Building for an exit (or not)

Thomas G Gunning

OPINION AND COMMENT

CORRESPONDENCE

974 *Auf wiedersehen*, agbiotech


975 Trace and traceability—a call for regulatory harmony

978 Do-it-yourself (DIY) pathology


979 Bypassing consent for research on biological material

981 Cost/success projections for US biodefense countermeasure development

983 Data completeness—the Achilles heel of drug-target networks



A microfluidic affinity analysis device with > 7,000 valves is capable of performing thousands of parallel experiments. Einav *et al.* use this device to isolate a small molecule against the HCV target NS4B (p 1019). Credit: Doron Gerber.



Modeling tissue-specific metabolic fluxes, p 1003



nature publishing group

Nature Biotechnology (ISSN 1087-0156) is published monthly by Nature Publishing Group, a trading name of Nature America Inc. located at 75 Varick Street, Fl 9, New York, NY 10013-1917. Periodicals postage paid at New York, NY and additional mailing post offices. **Editorial Office:** 75 Varick Street, Fl 9, New York, NY 10013-1917. Tel: (212) 726 9335, Fax: (212) 696 9753. **Annual subscription rates:** USA/Canada: US\$250 (personal), US\$2,730 (institution), US\$4,050 (corporate institution). Canada add 7% GST #104911595RT001; Euro-zone: €202 (personal), €2,170 (institution), €3,488 (corporate institution); Rest of world (excluding China, Japan, Korea): £130 (personal), £1,400 (institution), £2,250 (corporate institution); Japan: Contact NPG Nature Asia-Pacific, Chiyoda Building, 2-37 Ichigayatamachi, Shinjuku-ku, Tokyo 162-0843. Tel: 81 (03) 3267 8751, Fax: 81 (03) 3267 8746. **POSTMASTER:** Send address changes to *Nature Biotechnology*, Subscriptions Department, 342 Broadway, PMB 301, New York, NY 10013-3910. **Authorization to photocopy** material for internal or personal use, or internal or personal use of specific clients, is granted by Nature Publishing Group to libraries and others registered with the Copyright Clearance Center (CCC) Transactional Reporting Service, provided the relevant copyright fee is paid direct to CCC, 222 Rosewood Drive, Danvers, MA 01923, USA. Identification code for *Nature Biotechnology*: 1087-0156/04. **Back issues:** US\$45, Canada add 7% for GST. CPC PUB AGREEMENT #40032744. Printed by Publishers Press, Inc., Lebanon Junction, KY, USA. Copyright © 2008 Nature Publishing Group. Printed in USA.

COMMENTARY

- 985 **Toward biosimilar monoclonal antibodies**
Christian K Schneider & Ulrich Kalinke

BOOK REVIEW

- 991 **Context, context, context! A delicate empiricism for biotechnology**
Lenny Moss

FEATURE

PATENTS

- 993 **DNA-based patents: an empirical analysis**
Ann E Mills & Patti Tereskerz
- 996 **Recent patent applications in tissue culture**

NEWS AND VIEWS

- 997 **Dissecting microbial employment**
Elizabeth A Dinsdale & Forest Rohwer **b** see also p 1029
- 998 ***Agrobacterium*-mediated DNA transfer, and then some**
Stanton B Gelvin **b** see also p 1015
- 1000 **Viral attenuation by design**
Harriet L Robinson
- 1002 RESEARCH HIGHLIGHTS

COMPUTATIONAL BIOLOGY

ANALYSIS

- 1003 **Network-based prediction of human tissue-specific metabolism**
Tomer Shlomi, Moran N Cabili, Markus J Herrgård, Bernhard Ø Palsson & Eytan Ruppin

PRIMER

- 1011 **What are decision trees?**
Carl Kingsford & Steven L Salzberg


RESEARCH

BRIEF COMMUNICATIONS


- 1015 **T-DNA-mediated transfer of *Agrobacterium tumefaciens* chromosomal DNA into plants**
B Ülker, Y Li, M G Rosso, E Logemann, I E Somssich & B Weisshaar
b see also p 998

ARTICLES


- 1019 **Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis**
S Einav, D Gerber, P D Bryson, E H Sklan, M Elazar, S J Maerkl, J S Glenn & S R Quake



Agrobacterial genomic DNA in transgenic plants, p 1015



Drug discovery with a microfluidics chip, p 1019



Targeted metagenomics, p 1029

LETTERS

1029 High-resolution metagenomics targets specific functional types in complex microbial communities

M G Kalyuzhnaya, A Lapidus, N Ivanova, A C Copeland, A C McHardy, E Szeto, A Salamov, I V Grigoriev, D Suci, S R Levine, V M Markowitz, I Rigoutsos, S G Tringe, D C Bruce, P M Richardson, M E Lidstrom & L Chistoserdova

i see also p 997

1035 Photoswitchable fluorescent proteins enable monochromatic multilabel imaging and dual color fluorescence nanoscopy

M Andresen, A C Stiel, J Fölling, D Wenzel, A Schönlé, A Egner, C Eggeling, S W Hell & S Jakobs

1041 Predicting PDZ domain-peptide interactions from primary sequences

J R Chen, B H Chang, J E Allen, M A Stiffler & G MacBeath

NATUREJOBS BIOTECHNOLOGY

CAREERS AND RECRUITMENT

1047 Growing the bioscience career pipeline

Christine Shapard

NATURE BIOTECHNOLOGY CLASSIFIED


See back pages.

1050 PEOPLE


ADVERTISEMENT

Regional report: Basque Science


The Basque Region is a pole of innovation and competitiveness in southern Europe. This supplement, from Ikerbasque, the Basque Foundation for Science, follows Letters on p 1045 and explores the impressive results of Basque investment in science and technology.



©FMGB, Guggenheim Bilbao Museum, 2008



Photoswitchable fluorescent proteins,
p 1035



Predicting protein-protein interactions,
p 1041